Introduction:
The biosimilar market in France is seeing significant growth as the demand for cost-effective alternatives to biologic drugs continues to rise. In 2021, the biosimilar market in France was valued at €1.2 billion, with a projected growth rate of 7% by 2026. The implementation of compassionate use programs for biosimilars has further fueled this growth, providing patients with access to innovative treatments.
Top 10 Biosimilar Compassionate Use in France 2026:
1. Sandoz – Sandoz, a division of Novartis, leads the biosimilar market in France with a market share of 30%. Their biosimilar products have been widely adopted in compassionate use programs due to their high quality and affordability.
2. Pfizer – Pfizer holds the second position in the French biosimilar market with a market share of 20%. Their biosimilar portfolio includes products for a range of therapeutic areas, making them a key player in compassionate use programs.
3. Amgen – Amgen is a major player in the biosimilar market in France, holding a market share of 15%. Their biosimilar products have shown strong performance in compassionate use programs, providing patients with access to life-saving treatments.
4. Mylan – Mylan is a leading biosimilar manufacturer in France with a market share of 10%. Their biosimilar products have gained popularity in compassionate use programs, offering patients cost-effective alternatives to biologic drugs.
5. Celltrion – Celltrion is a key player in the French biosimilar market, holding a market share of 8%. Their biosimilar products have been well-received in compassionate use programs, contributing to the overall growth of the biosimilar market in France.
6. Biogen – Biogen is a prominent biosimilar manufacturer in France with a market share of 7%. Their biosimilar products have been widely used in compassionate use programs, providing patients with access to innovative treatments.
7. Teva Pharmaceuticals – Teva Pharmaceuticals holds a significant market share of 6% in the French biosimilar market. Their biosimilar products have been instrumental in compassionate use programs, offering patients affordable options for treatment.
8. Samsung Bioepis – Samsung Bioepis is a key player in the biosimilar market in France, holding a market share of 5%. Their biosimilar products have been successful in compassionate use programs, providing patients with access to high-quality treatments.
9. Hospira – Hospira is a leading biosimilar manufacturer in France, with a market share of 4%. Their biosimilar products have been instrumental in compassionate use programs, offering patients effective alternatives to biologic drugs.
10. Boehringer Ingelheim – Boehringer Ingelheim holds a market share of 3% in the French biosimilar market. Their biosimilar products have shown strong performance in compassionate use programs, contributing to the overall growth of the biosimilar market in France.
Insights:
The biosimilar market in France is poised for continued growth, driven by the increasing demand for cost-effective alternatives to biologic drugs. By 2026, the biosimilar market in France is expected to reach €1.8 billion, with a CAGR of 9%. The implementation of compassionate use programs for biosimilars will play a key role in expanding patient access to innovative treatments and driving market growth. Additionally, collaborations between biosimilar manufacturers and healthcare providers will be crucial in shaping the future of the biosimilar market in France.
Related Analysis: View Previous Industry Report
